P8A:SGX
Cordlife Group Ltd
0,12 SGD
0,00%
(0,00) 1D
12. lis, 09:49:20 GMT+8 · SGD
search
Svi simboli
| Simbol | Cijena | Promjena | Postotna promjena |
|---|
insights_autoGeneriranje najvažnijih uvida za P8A...
Trž. kap.
32,37 mil.
Prosj. kol.
1,32 tis.
Količina
0,00
52-tjed. najviša
0,26 SGD
52-tjed. najniža
0,10 SGD
EPS
−0,04 SGD
Dionice u optjecaju
267,53 mil.
Broj djelatnika
111
Trž. kap.
32,37 mil.
Prosj. kol.
1,32 tis.
Količina
0,00
52-tjed. najviša
0,26 SGD
52-tjed. najniža
0,10 SGD
EPS
−0,04 SGD
Dionice u optjecaju
267,53 mil.
Broj djelatnika
111
Vijesti
Iz web-izvora i od partnera za vijesti
Financije.hr
·
prije 1 dan
Wall Street pred otvaranjem: Rotacija iz tehnologije jača, Dow preuzima vodstvo
tech-insider.org
·
prije 1 sat
Trump Calls AI Warnings ‘HOAX’, Nasdaq Drops 0.9% [2026]
Yahoo Finance
·
prije 15 sati
Wall Street’s record breakouts unravel as investors dump recent winners: Chart of the Day
MarketWatch
·
prije 1 dan
Don’t buy this dip: Several signs suggest there’s more pain ahead for tech stocks
Profil
Cordlife Group Limited, is a consumer health company incorporated in May 2001 and a provider of cord blood and cord lining banking services in Asia. Cordlife has been listed on the mainboard of SGX since March 2012.
Cordlife Group owns the largest network of cord blood banks in Asia with full stem cell processing and storage facilities in six markets including Singapore, Hong Kong, India, Indonesia, and the Philippines. Beyond cord blood and cord lining banking, Cordlife offers diagnostics services, particularly for the mother and child segment, including urine-based newborn metabolic screening, non-invasive prenatal testing, paediatric vision screening and family genetic screening services.
Cordlife's stem cell processing and storage facilities in Singapore, Hong Kong, India, Indonesia, the Philippines and Malaysia were accredited by AABB until 2024 when its accreditation was withdrawn.
In November 2023, the Ministry of Health of Singapore revealed that Cordlife Group had exposed cryopreserved cord blood units at suboptimal temperatures, damaging the cord blood units belonging to at least 2,150 clients and rendering them unsuitable for stem cell transplant purposes. Wikipedia
Cordlife Group Ltd – informacije
Glavni izvršni direktorYiu Pang Fai
Zaposlenici111
Osnovano2. svi 2001.
Sjedište-
SektorHealth care provider
Web-lokacijacordlife.com